sulaco, the science community knows since long that Bavi has a potential that is an existential thread for that BP that isn't going to get the partnerships or in the end the ownership of PPHM. I even suspect PPHM to play it down exactly for that reason.
All will become clear with the presentation about Breast Cancer (the IST) because our previous breast cancer clinical trial is the one that trigger all the back-stage stuff.
That trial, with it's 5 patients that did so extremely well that it probably must have scared some people. You know my logic, you don't present failures at ASCO and what is more in the case of Breast Cancer IST - PPHM was under NO obligation to schedule this presentation in. I think we ALL where surprised it was listed in FTM's post with the 3 presentations.
So that question of yours is easily answered and I'll rephrase it before because Bungler has been asking the exact same question for some while:
"Why do some invest so much attention and effort in bashing PPHM/Bavi, in contrast to other small cap Biotech companies and drugs, while it is only one drug out of thousands in progress of development?"
The answer is simple, straight-forward and illustrated with an example by Kramer in the video where he discloses how they play it (The Apple iPhone & Verizon example).
As long as the public and the markets have no certainty, and you know something for sure, then promote the opposite, don't hesitate to lie and manipulate the public, II, Funds, say the market in general, and make sure you short before doing so. You'll cash on the short in step 1!
In step two cover your short position slowly and start loading the shelf (long) and wait for the news, that your already know, to come out and the market go wild! Sell in full demand once you see the market makers moving to the Ask (that means there are no more shares from regular sellers and you bring your volume in and retract up slowly so that you make better and better prices. MM MUST back off, they have lots of advantages in trading but they CANNOT (may not) precede market quotes in the Bid and Ask. They make market when liquidity is gone (and therefor can make better profits).
All the AF, DD, PC, eMaganzines, Twitter channels, board activity is part of such PPHM show. Why, because on these board you do not only find people that research in depth and do DD but also all those that don't and try to "quickly" find out what to invest in based on the comments of others. At that point the voice of a guy like Kramer on a CNBC show or the endorsement of the WSJ carry different weight but many people read the free internet eMagazines.
The fact that PPHM and Bavi are continuously under attack is indeed a good sign, certainly as the drug has proven to be very safe and and is working well and this continuously and consistently over time.
Just as a small support of the position I am defending here: Have you noticed how PPHM is continuously on the "Most Read" page (Top 50) of IHub's more then 21000 boards! Why are all other small biotechs not there? Some have PIII approved drugs and if you see them on the page it is only the day something happens to the pps. Why is DD's Biotech Values board, who talks about way more biotech stocks then just PPHM only, not continuously higher ranked. One would think "more stocks, more readers". But it isn't the so if we add PPHM to the lot and so yes, PPHM gets continuously disproportional attention from the market.
But remember, once the market will officially know, that will be ASCO, these games will come to an end and others will start. Bigger boys will come in compared to the plankton that can play now because the pro's will get interested after ASCO and /or a FDA PIII for Bavi. Piper Jaffrey covering PPHM now is a pre-sign of that!
The plankton that plays now knows that at that moment there will be insufficient shares to serve the pro's, and in contrast to many of us, the pro's don't care to pay 5 or even 10$ for a stock with the potential of PPHM with Bavi in its pipeline because they know very well that a BP will have it some day. It is just a matter of time & price. With the oncology markets alone, and with NO patents based Bavi product on the market yet and therefore a long potential exclusive exploitation period, paying 150$ ps for PPHM would still be a golden deal for a BP. If they would only do 10 Billion a year with Bavi (Avastin alone does 4Billion and it kills you in the process) then that would be 75$ pss per year. Payback in two years, say 3 to cover some production and distribution cost because Bavi will need few marketing and sell itself but its manufacturing is relatively cheap).
So what is 5 or 10$ today for pro's if they can get that kind of leverage. If we get back to 5$+ and stay there (no more Sept 24th alike PR's) then things will accelerate (as they would have since Sept 2012 without the data discrepancy PR). The road from 5 to 10$ is easier then from 1 tot 2$. When you are at 5$ you have something that is undone of doubt and uncertainty! That is where the big pro's really step in because it means business!
News 
Market Data 
Discover 
AI
